In contrast, pre-B ALL patients who did not attain a complete remission (n = 10) after the first bortezomib cycle showed unaltered NF-kB activity after bortezomib treatment (Fig. 4c). The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.